Multicenter Phase II Study of Panitumumab and Irinotecan with or without Fluoropyrimidines in patients with KRAS Wild-type Metastatic Colorectal Cancer (PACIFIC)
Phase 2
- Conditions
- colorectal cancer
- Registration Number
- JPRN-UMIN000007658
- Lead Sponsor
- Epidemiological and Clinical research Information Network (ECRIN)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
1) Brain metastasis (symptomatic) 2) Diarrhea 3) Intestinal paralysis or obstruction 4) With infectious diseases or febrile condition 5) With severe pulmonary diseases (interstitial pneumonitis, pulmonary fibrosis) 6) With severe diseases ( DM, heart failure, renal failure, liver dysfunction) 7) Pregnant or possibly pregnant, and nursing women 8) Carcinomatous menigitis, history of mental or cerebrovascular disorder 9) With grade 3 peripheral neuropathy 10) Administration of contraindicative medicines 11) History of administration of antagonisms to EGF signal 12) Other conditions not suitable for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival
- Secondary Outcome Measures
Name Time Method Response rate Overall survival Disease control rate Adverse events Biomarkers on clinical examination data